Eisbach Bio

Eisbach is an innovative start-up in biotechnology.
We are developing novel drugs that successfully target molecular vulnerabilities arising in cancer genomes.

[NUCLEAR-DN @NuclearDn]

🚨 2nd Recruitment call is now open! ����

⚠️There are still 3 Doctoral Candidate positions available in NUCLEAR!

If you're ready to dive into innovative research in metabolic regulation of genome, join our international program.

📩Apply now: https://t.co/XvmZJK10VW

[NUCLEAR-DN @NuclearDn]

🚨 16 PhD positions open in early 2025! 🚀 Join NUCLEAR for cutting-edge research on nuclear metabolism, cell identity, and genome function. 🌍 Details on projects, eligibility & applications coming soon.Stay tuned!
#PhDOpportunities#MarieCurieActions
👉https://t.co/l2OJ0DdbFd

[Eisbach Bio @eisbachbio]

🌟 Eisbach Bio 🤝 Texas 🌟

We are proud to announce that Eisbach has received a Texas Therapeutics Company Award from the Cancer Prevention and Research Institute of Texas (@CPRITTexas) to support the clinical development of EIS-12656!

Read more: https://t.co/K7KWIqz6hV

[NUCLEAR-DN @NuclearDn]

📢 Visit our press release published today to learn about the exciting NUCLEAR project, coordinated by @MarcusBuschbeck at the @CarrerasIJC . Discover more about training new experts in #metabolic regulation of #genome function! 🧬✨ Read more: https://t.co/oziwBtgm6s

[Eisbach Bio @eisbachbio]

🧬 Shaping the Future of #Biomedicine with the NUCLEAR project 🧬

Eisbach is set to train the next generation of scientists in the #metabolic regulation of genome function through the EU-funded research network NUCLEAR 🌍

Read the press release here: https://t.co/K7KWIqzE7t

[Eisbach Bio @eisbachbio]

The @US_FDA has granted Eisbach Bio IND approval for its drug candidate EIS-12656, 👏, the world's first small molecule ##therapy targeting the molecular machine ALC1, which is key #DNA damage and repair in several solid #tumor indications.

Learn more: https://t.co/K7KWIqz6hV

[Eisbach Bio @eisbachbio]

Eisbach is excited to announce a $4.5 million investment from the Cancer Focus Fund to support its first-in-human Phase 1/2 #Trial of EIS-12656 for refractory advanced solid #tumors. Read the press release: https://t.co/K7KWIqz6hV

[Eisbach Bio @eisbachbio]

Eisbach is proud to announce the start of a Phase 1, first-in-human clinical trial for EIS-10700, a COVID-19 antiviral targeting the RNA helicase of SARS-CoV-2.

Read the full press release here:
https://t.co/K7KWIqz6hV

#clinicaltrials #covid19 #drugdevelopment #TeamEisbach

[Eisbach Bio @eisbachbio]

A nucleic acid chemistry cluster to shape Germany’s R&D future – @eisbachbio member of the winning C-NATM cluster.

The cluster has emerged as one of the winners in the Clusters4Future competition funded by BMBF. Read more about our collaboration:

https://t.co/4Kv4Wi5Pu1

[UT MD Anderson @UTMDAnderson]

“In our collaboration with Eisbach, we are hoping to advance additional much-needed therapeutic options that can improve patients’ lives,” says our Dr. Philip Jones: https://t.co/OwEMgzfhpa @eisbachbio #CancerMoonshot #EndCancer

[UT MD Anderson @UTMDAnderson]

We’re proud to collaborate with Eisbach to jointly discover and develop precision oncology drugs that target synthetic lethal engines key to tumor genome evolution: https://t.co/SfQm8Xf7Zk @eisbachbio #CancerMoonshot #EndCancer

[Eisbach Bio @eisbachbio]

@Eisbachbio is excited to announce a strategic research collaboration with The University of Texas @MDAndersonNews to jointly develop medicines targeting epigenetic machinery in oncology. Read the full press release here:

https://t.co/Gkpt8vhWuj

#oncology #research

[Eisbach Bio @eisbachbio]

@Eisbach is excited to announce a strategic research collaboration with The University of Texas @MDAndersonNews to jointly develop medicines targeting epigenetic machinery in oncology. Read the full press release here:

https://t.co/Gkpt8vhWuj

#oncology #research

[Eisbach Bio @eisbachbio]

Join our fight against cancer!
To leverage our allosteric platform, we are growing our incredible team and are now recruiting (d/f/m) in Munich:

- Full-time Principal Scientist and
- Full-time Laboratory Head

Let's treat cancer smarter. Together.

https://t.co/uZ5RpNHTqC

[Eisbach Bio @eisbachbio]

Eisbach Bio is thrilled to announce financial support of €6.7M from the Bavarian Government for the development of targeted SARS-CoV-2 antivirals.

More details about the BayTherapie grant in our press release:

https://t.co/U92L0o6lT8

#BayTherapie2020 #COVID19 #TeamEisbach

[BioM Biotech Cluster Development @BioM_Munich]

🚀 Start-up - pandemic - success: How does that go together?
Find out in the panel discussion: How to lift off during a pandemic - news from the frontline at our upcoming start-up event
w/ @Tubulis_GmbH #ViGeneron @eisbachbio @deepchealth @HorstDomdey
▶️ https://t.co/VHC3tK1CNt

[Laborjournal @Lab_Journal]

Im Frühjahr erzählten uns die #Onko­logie-Experten von @eisbachbio, dass sie auch an einem #Corona-Medikament arbeiten. Nun ist es „kurz vor der Klinik“. Allerdings: „Es hat gedauert, die Politik zu überzeugen“ … @SigridMaerz fragte nach: https://t.co/YMcPX8mYtr

[Eisbach Bio @eisbachbio]

Exploiting deep learning to develop sustainable COVID-19 inhibitors! Eisbach announce a collaboration with @uni_kl to develop small molecule inhibitors that will target the virus for the long-term.

Read the press release here: https://t.co/tM55eMiEII

#mutations #DeepLearning

[BMFTR @bmftr_bund]

💊 Das #BMBF fördert gezielt die Entwicklung von aussichtsreichen Medikamenten gegen #COVID19. Jetzt starten 8 neue Forschungsvorhaben. BM Anja #Karliczek: "Wir brauchen weiterhin wirksame Medikamente gegen COVID-19."
👉 https://t.co/tjfKgAvpQX
#Corona #Forschung

[Eisbach Bio @eisbachbio]

Congratulation to all COVID-19 projects funded by the BMBF! We are very proud to be part of this team effort against #SARS_CoV_2 and to continue our drug development with the @BMBF_Bund support

[BMFTR @bmftr_bund]

https://t.co/m0kFoLm006